|
Prescription Drug Search
Strengths available for Vigabatrin :
Strengths available for Vigabatrin sachet:
Browse Alphabetically:
A
·
B
·
C
·
D
·
E
·
F
·
G
·
H
·
I
·
J
·
K
·
L
·
M
·
N
O
·
P
·
Q
·
R
·
S
·
T
·
U
·
V
·
W
·
X
·
Y
·
Z
·
#
Information about CancerDrugsDirect.com
List of countries where we can ship Vigabatrin:
- Albania
- Antigua and Barbuda
- Armenia
- Australia
- Austria
- Bangladesh
- Belgium
- Bermuda
- Bosnia and Herzegovina
- Brazil
- Chile
- Cook Islands
- Denmark
- Dominican Republic
- Germany
- Guam
- Hong Kong
- Hungary
- Iceland
- India
- Iraq
- Italy
- Jordan
- Kuwait
- Lebanon
- Liechtenstein
- Mauritius
- Moldova, Republic of
- Netherlands Antilles
- Panama
- Paraguay
- Philippines
- Portugal
- Saint Lucia
- Slovakia
- Tonga
- United Arab Emirates
- United Kingdom, UK
- United States, US
- Venezuela
Latest news releases on Vigabatrin:
Catalyst Pharmaceutical Partners Reports Positive Results From Phase I(a) Clinical Study of CPP-115 - msnbc.com
CPP-115 is a novel GABA aminotransferase inhibitor and vigabatrin analogue that, based on preclinical studies to-date, is greater than 100 times more potent than vigabatrin and may have reduced side effects (e.g., visual field defects ...
Catalyst Pharmaceutical Partners Announces Completion of Enrollment in CPP-109 Phase II(b) Clinical Trial for the Treatment of Cocaine Addiction - Yahoo Finance
CORAL GABLES, Fla., May 21, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX - News) today announced that patient enrollment in its CPP-109 vigabatrin Phase II(b) clinical trial has reached its goal of 200 cocaine ...
Catalyst Pharmaceutical Partners Announces First Quarter 2012 Financial Results - Yahoo Finance
Catalyst has two products in development, and is currently evaluating its lead product candidate, CPP-109 (vigabatrin), for the treatment of cocaine dependency. CPP-109 has been granted "Fast Track" status by the U.S. Food & Drug Administration ...
Catalyst Pharmaceutical Partners, Inc. : Catalyst Pharmaceutical Partners Announces First Quarter 2012 Financial Results - 4-traders (press release)
Catalyst has two products in development, and is currently evaluating its lead product candidate, CPP-109 (vigabatrin), for the treatment of cocaine dependency. CPP-109 has been granted "Fast Track" status by the U.S. Food & Drug Administration (FDA ...
